| Oct 16 |
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
|
| Oct 15 |
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
|
| Oct 15 |
Castle Biosciences price target raised to $40 from $35 at BTIG
|
| Oct 15 |
Castle Biosciences, Inc.'s (NASDAQ:CSTL) Intrinsic Value Is Potentially 95% Above Its Share Price
|
| Oct 15 |
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
|
| Oct 14 |
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
|
| Oct 11 |
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
|
| Oct 9 |
Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...
|
| Oct 9 |
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
|
| Oct 7 |
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
|
